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Abstract: Mucocutaneous candidiasis (MC) is one of the ﬁ  rst signs of human immunodeﬁ  ciency 
virus (HIV) infection. Over 90% of patients with AIDS will eventually develop oropharyngeal 
candidiasis (OPC) at some time during their illness, and an additional 10% will develop esopha-
geal candidiasis (EC). Although numerous antifungal agents are available, azoles, both topical 
(clotrimazole) and systemic (ﬂ  uconazole, itraconazole), have replaced older topical antifungals 
(gentian violet and nystatin) in the management of MC in these patients. The systemic azoles, 
itraconazole and ﬂ  uconazole, are generally safe and effective agents in HIV-infected patients 
with MC. A concern in these patients is the clinical relapse, which appears to be dependent on 
degree of immunosuppression and is more common following clotrimazole and ketoconazole 
than with ﬂ  uconazole or itraconazole. Posaconazole is a new extended-spectrum triazole 
recently approved for the management of OPC. In vitro, posaconazole possesses potent activity 
against numerous Candida species, including strains that are resistant to ﬂ  uconazole. Recent 
clinical trials demonstrate that posaconazole is as efﬁ  cacious as ﬂ  uconazole in producing a 
successful clinical response in HIV-infected patients with OPC/EC. In addition, posaconazole 
was safe and more effective in sustaining clinical success after treatment was discontinued. 
Posaconazole appears to be an effective alternative in the management of MC in this difﬁ  cult- 
to-treat population.
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Introduction
Symptomatic mucosal candidiasis (MC) arises in subjects colonized with Candida 
who are predisposed by illness, debility, or a local reduction in host resistance to an 
overgrowth of their own indigenous ﬂ  ora (Odds 1988; Vazquez and Sobel 2003). 
Colonization rates increase with severity of illness and duration of hospitalization 
(Johnston et al 1967).
Oral candidiasis has been described since Hippocrates, although Hippocrates 
used the term “aphthae” to describe this infection (Hippocrates and Adams 1939). 
Several clinical forms of oral candidiasis exist; thrush is the most commonly and 
widely recognized and is also called acute pseudomembranous candidiasis. Oro-
pharyngeal candidiasis (OPC) may be the ﬁ  rst manifestation of HIV infection and, 
approximately 80%–90% of patients with AIDS will develop oral candidiasis at some 
stage (Coker et al 1995; Silverman et al 1996). Although not as frequent as OPC, 
esophageal candidiasis (EC) is reported in approximately 10% of patients with AIDS, 
and unlike OPC, is capable of producing incapacitating illness, wasting syndrome, 
and malnutrition (Dupont et al 1994; Moore and Chaisson 1996). In addition, MC 
also occurs in individuals with underlying hematological malignancy, following solid 
organ transplantation, in those with congenital cell-mediated immune dysfunction, and 
following prolonged antimicrobial therapy (Jensen et al 1964; Johnston et al 1967; 
Scott and Jenkins 1982).Therapeutics and Clinical Risk Management 2007:3(4) 534
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Even in the era of highly active antiretroviral therapy 
(HAART), HIV-infected individuals continue to suffer 
from recurrent OPC/EC (Vazquez and Sobel 2003; Pappas 
et al 2004). With the advent of HAART fewer HIV-infected 
patients are developing OPC/EC. In contrast, rate of OPC 
and EC has not been altered in developing countries where 
HAART is not readily available. Antiretroviral therapy 
has not altered the relative frequency of AIDS-deﬁ  ning 
illnesses, and OPC/EC remains among the most common. 
Mucocutaneous candidiasis is usually seen in those patients 
with CD4+ counts less that 100/mm3 (Imam et al 1990; 
Moore and Chaisson 1996; Vazquez and Sobel 2003). In 
a population of individuals with median CD4+ counts of 
100–110/mm3, the incidence of esophageal candidiasis is 
approximately 4 per 100 person-years of observation (Moore 
and Chaisson 1996).
In the non-HIV infected individual, C. albicans accounts 
for approximately 70% – 80% of oral isolates, while C. glabra-
ta and C. tropicalis account for approximately 5%–8% each, 
and the other non-albicans Candida species are recovered only 
rarely (Vazquez and Sobel 2003). C. albicans is the species 
most often implicated in OPC/EC, consistently accounting 
for 90% or more of baseline isolates (Moore and Chaisson 
1996; Wilcox et al 1997; Pappas et al 2004). There has been a 
signiﬁ  cant increase in the frequency of non-albicans Candida 
species isolation in the HIV-infected individual (Barchiesi et al 
1993; van’t Wout 1996). In the 1980s, non-albicans Candida 
species accounted for 3%–4 % of oral isolates recovered from 
HIV-infected patients, while in the 1990s, 17% of isolates 
recovered from HIV patients were non-albicans Candida 
species (Barchiesi et al 1993; van’t Wout 1996).
Therapy
Prompt therapy with an antifungal agent is indicated 
(Vazquez and Sobel 2003; Pappas et al 2004). Unfortunately, 
almost all patients with AIDS and successfully treated MC 
will eventually develop a recurrence in the absence of 
immune reconstitution (Reef and Meyer 1995). Therefore, in 
addition to antifungal therapy, antiretroviral therapy should 
be instituted as soon as possible.
Although safe and efﬁ  cacious therapies are available, 
among the presently available armamentarium, all agents 
have some limitations. Topical agents may be used for OPC, 
but are ineffective for EC. Numerous antifungal agents are 
available for the treatment of OPC (Table 1) and EC (Table 2). 
However, several factors must be considered when choosing 
antifungal agents for patients with HIV or AIDS. One impor-
tant factor is efﬁ  cacy. In HIV-positive patients, antifungals 
are less efﬁ  cacious than in patients with cancer, and time to 
antifungal response is also more prolonged (Darouiche 1998). 
In addition, the relapse rate is higher in patients with HIV than 
in other patient populations (Darouiche 1998; Vazquez 1999). 
Therefore, certain predisposed HIV-positive patients experi-
ence recurrent episodes of OPC and subsequently receive 
numerous courses of antifungals during their lifetime. As 
AIDS progresses, they frequently experience shorter intervals 
between episodes of OPC and esophageal candidiasis and 
thus more antifungal exposure, which may lead to antifungal 
resistance and severe morbidity (Vazquez and Sobel 1997).
Another possibly more important factor to consider 
when managing recurrent fungal infections in HIV-positive 
patients is the long-term consequences of antifungal therapy 
on mycoﬂ  ora. It is important to note that, as with many 
infections in this patient population, antifungal treatment 
merely reduces the signs and symptoms of infection, and 
Table 1 Antifungals for the treatment of oropharyngeal candidiasis
Antifungal
 agent  Form  Strength  Use
Topical
Nystatin Pastille  200,000  units  Dissolve  1–2
     pastilles  qid
Nystatin  Suspension  100,000 units  5 mL swish and
     swallow  qid
Clotrimazole  Oral troche  10 mg  Dissolve 1 troche
     5  times/day
Amphotericin B  Suspension  1 mg/mL  1 mL swish and
     swallow  qid
Amphotericin B  Lozenge  100 mg  qid
Amphotericin B  Tablet  10 mg  qid
Systemic
Ketoconazole  Tablet  200 mg  1–2 tablets qd-bid
Fluconazole  Tablet  100 mg  1 tablet qd
Fluconazole  Solution  10 mg/mL  10 ml qd
Itraconazole  Capsule  100 mg  200 mg qd
Itraconazole  Solution  10 mg/mL  10–20 ml qd-bid
Posaconazole  Suspension  100 mg/2.5 mL  100 mg qd
Derived from data of Vazquez and Sobel (2003)
Notes: qid, four times daily; tid, three times daily; bid, twice daily; qd, once daily
Table 2  Antifungals for the treatment of esophageal candidiasis
Antifungal Agent  Form  Strength  Use
Ketoconazole  Tablet  200 mg  1–2 tablets qd-bid
Fluconazole  Tablet  100 mg  1 tablet qd
Fluconazole  Solution  10 mg/mL  10 mL qd
Itraconazole  Capsule  100 mg  200 mg qd
Itraconazole  Solution  10 mg/mL  10–20 mL qd-bid
Voriconazole  tablet  200 mg  1 tablet bid
Derived from data of Vazquez and Sobel (2003)
Notes: bid, twice daily; qd, once daily Therapeutics and Clinical Risk Management 2007:3(4) 535
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thus produces a transient clinical response by lowering the 
quantity of organisms in the affected area. It is difﬁ  cult to 
eradicate yeast from the body of a patient infected with 
HIV (Vazquez and Sobel 1997; Vazquez and Sobel 2003). 
Subsequently, this leads to numerous courses of antifungals, 
development of antifungal resistance, and frequently, antifun-
gal cross-resistance (Maenza et al 1997). This is reﬂ  ected by 
the clinical ineffectiveness of antifungals to which a patient 
has not previously been exposed. Thus we are becoming 
increasingly aware that choosing the appropriate agent, even 
in the early stages of disease, is extremely important because 
of the future repercussions of this selection in the advanced 
stages of disease.
Presently available therapy which includes topical agents 
such as nystatin, amphotericin B, and clotrimazole are all 
somewhat effective, but tolerance and compliance are fre-
quently problematic (Kozinin et al 1957; Quintiliani et al 
1994; Vazquez 1999). In addition, topical agents are inef-
fective in EC, thus mandating systemic antifungal therapy 
(Vazquez 1999).
Nystatin is the time-honored treatment for oral thrush 
in otherwise healthy adults and infants. Its limitations 
include bitter taste, gastrointestinal (GI) side-effects, and 
a 4 times a day regimen, all of which eventually lead to 
reduced adherence and lower efﬁ  cacy (Pons et al 1997; 
Vazquez 1999). More importantly, is its lack of efﬁ  cacy 
in severely immunocompromised patients, such as those 
with HIV/AIDS (Quintiliani et al 1994; Pons et al 1997). 
In a published study comparing the efﬁ  cacy of nystatin 
and oral ﬂ  uconazole in HIV-positive patients, the clinical 
cure rate of nystatin was 52%, compared with 87% for 
ﬂ  uconazole (Pons et al 1997). The mycological cure rate 
was also signiﬁ  cantly lower for nystatin (6% vs 60%). In 
addition, the relapse rates 28 days after the end of therapy 
were 44% and 18%, respectively.
Amphotericin B oral suspension is also an alterna-
tive antifungal agent (Kozinin et al 1957; Vazquez 1999). 
In addition to the suspension, amphotericin B is also available 
as a lozenge and tablet. Like nystatin, it is not absorbed from 
the GI tract and must to be given 4 times daily; however, it 
does not have an unpleasant taste. Unfortunately, compara-
tive studies evaluating amphotericin B oral solution and other 
antifungals are limited.
Azole antifungals have essentially replaced the topical 
polyene agents for the treatment of OPC in AIDS (Como and 
Dismukes 1994). Clotrimazole 10 mg troches administered 
5 times/day were successful in treating mild-to-moderate 
OPC during the early stages of HIV disease and during the 
initial episodes of oral candidiasis in patients with neoplastic 
diseases (Schectman et al 1984). In a study comparing oral 
ﬂ  uconazole and clotrimazole troches for oral candidiasis in 
persons with HIV or AIDS, efﬁ  cacy was essentially the same, 
98% and 94%, respectively (Pons et al 1993). At the end 
of antifungal therapy, ﬂ  uconazole was more effective than 
clotrimazole in eradicating detectable yeast from the oral ﬂ  ora 
(65% vs 48%, respectively). In addition, patients receiving 
ﬂ  uconazole were also more likely to remain asymptomatic 
through the second week of follow-up (82%) when compared 
with those receiving clotrimazole (50%).
Although topical therapy is frequently effective and 
relatively inexpensive, recurrent episodes of OPC in more 
advanced disease often require systemic azoles such as keto-
conazole, ﬂ  uconazole, itraconazole, and now posaconazole. 
Ketoconazole was the ﬁ  rst available oral systemic imidazole 
antifungal agent and is highly effective even in debilitated 
patients (Como and Dismukes 1994). Clinical cure rates in 
excess of 75% have been achieved with daily ketoconazole 
administered for 10–14 days (Hughes et al 1993). In several 
comparative trials in patients with AIDS, ketoconazole was 
not as efﬁ  cacious as ﬂ  uconazole (70%–80% vs 94%–100%), 
and the mycological cure rates were also lower (DeWit et al 
1989; Como and Dismukes 2003). Use of ketoconazole is 
limited by fears of hepatotoxicity and drug-drug interactions, 
and concerns about the reliability of gastric absorption and 
subsequent blood and tissue levels (Como and Dismukes 
1994; Vazquez 1999). The drug’s absorption is mark-
edly reduced under hypochlorhydric states. Thus, systemic 
absorption is a concern in patients with AIDS-related hypo-
chlorhydria, and in those receiving H2-receptor antagonists 
(cimetidine, ranitidine,), sucralfate, antacids, didanosine, 
and proton pump inhibitors (omeprazole, lansoprazole) 
(Piscitelli et al 1996). In addition, since ketoconazole is a 
potent inhibitor of the cytochrome (CYP) P450 3A4 enzyme 
system, numerous reports describe interactions with the non-
sedating H1-receptor antagonists (terfenadine, astemizole) 
and cisapride resulting in signiﬁ  cant prolongation of the QT 
interval and occasional deaths due to cardiac dysrhythmias 
(Honig et al 1993; Meyer and Rodvold 1996). Thus, concomi-
tant administration of ketoconazole with drugs metabolized 
via the same pathway (cyclosporine, digoxin, HIV-protease 
inhibitors, and several sedatives such as triazolam and mid-
azolam) may produce increased levels of the second drug 
(Meyer and Rodvold 1996).
The older triazoles, ﬂ  uconazole and itraconazole, have 
demonstrated excellent efﬁ  cacy and safety proﬁ  les for many 
years, and have become the most frequently prescribed Therapeutics and Clinical Risk Management 2007:3(4) 536
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antifungals, especially for patients with HIV or AIDS (Hay 
1990; Meunier et al 1990; Murray et al 1997). The clini-
cal efﬁ  cacy of ﬂ  uconazole 50–100 mg/day was evaluated 
in several open-label and placebo-controlled trials and in 
double-blind comparative studies versus clotrimazole or ke-
toconazole in patients with either hematologic or solid organ 
malignancy or HIV infection (Hay 1990; Koletar et al 1990; 
Meunier et al 1990). Although most studies utilized a 100 mg 
daily dose, clinical efﬁ  cacy has been achieved with a dose 
of 50 mg/day (Hay 1990). Clinical response was achieved in 
80% of patients with severe underlying disease with the low 
dose of ﬂ  uconazole. However, complete mycological cure is 
more difﬁ  cult to attain. A striking feature of ﬂ  uconazole is the 
rapidity of response, usually within 10 days with ﬂ  uconazole 
50 mg/day and within 5 days with 100–200 mg/day, even in 
the most severe forms of thrush associated with AIDS (Hay 
1990; Darouiche 1998). In addition, overall clinical response 
rates indicate that failure is rare, and in most published 
studies, 80% or more of patients were clinically cured, with 
another 10%–15% experiencing considerable improvement 
(Vazquez 1999).
Itraconazole has a broad spectrum of activity, and like 
other azoles, it inhibits the synthesis of fungal ergosterol. 
Since the capsule formulation has variable absorption, a 
cyclodextrin solution formulation has been developed and 
is generally the formulation utilized in OPC/EC (Barone 
et al 1998). In a pharmacokinetic study, the solution dem-
onstrated a 30% increase in itraconazole absorption. In 
addition, the solution has a much greater bioavailability in 
fasting patients compared with post-prandial administration 
(Hostetler et al 1992; Van de Velde et al 1996). A prospec-
tive, randomized trial in HIV-positive and AIDS patients with 
OPC, compared itraconazole oral solution 200 mg/day and 
ﬂ  uconazole 100/mg day for 14 days (Graybill et al 1998). 
Clinical response rates were 97% for itraconazole and 87% 
for ﬂ  uconazole, with few adverse events in both groups. 
However, approximately 50% of the patients in both groups 
experienced relapses at the 1-month follow-up evaluation.
Overall, itraconazole and ﬂ  uconazole, have demonstrated 
an improved safety proﬁ  le compared with other antimy-
cotic agents; nevertheless, they must be used with caution. 
Itraconazole has similar drug interactions as ketoconazole 
due to the inhibition of the same CYP3A4 enzyme system 
(Hostetler et al 1992; Meyer and Rodvold 1996). Fluconazole 
is associated with fewer drug-drug interactions because it 
has less afﬁ  nity for the enzyme (Kowalsky and Dixon 1991; 
Meyer and Rodvold 1996). The pharmacological interactions 
with ﬂ  uconazole include phenytoin, rifampin, rifabutin, 
cyclosporin A, and possibly some of the protease inhibitors 
(Kowalsky and Dixon 1991; Tucker et al 1992; Meyer and 
Rodvold 1996). In certain situations, ﬂ  uconazole may offer 
an advantage over ketoconazole or itraconazole because of 
the lower potential to produce drug-drug interactions.
The optimal antifungal agent for OPC is not known, but 
evaluation of the most recent literature seems to suggest that 
until now ﬂ  uconazole and itraconazole appear to be the most 
appropriate agents in patients with HIV infection or AIDS.
Since topical agents are ineffective in the management 
of EC, relatively few oral drugs for systemic infection are 
available (Vazquez and Sobel 2003; Pappas et al 2004). 
The current guidelines of the Infectious Diseases Society of 
America recommend the use of systemic antifungal therapy 
(Pappas et al 2004). Currently available therapy includes 
oral and parenteral azoles (ketoconazole, ﬂ  uconazole, itra-
conazole, and voriconazole) or parenteral polyenes (ampho-
tericin B). More recently, the echinocandins (caspofungin 
[Cancidas®, Merck & Co., Inc.]; micafungin [Mycamine®, 
Astellas Pharma US, Inc.]; and anidulafungin [Eraxis®, Pfizer 
Inc.]) have all been approved for the treatment of EC.
Amphotericin B, the agent of choice for many years is 
no longer acceptable as ﬁ  rst line therapy in most situations 
due to unacceptable nephrotoxicity and infusion-related 
reactions.
Voriconazole (Vfend®, Pfizer Inc.) is a newer triazole that 
has been shown to be 10- to 500-fold more potent in vitro 
than ﬂ  uconazole against a wide spectrum of fungi, including 
ﬂ  uconazole resistant Candida species (Como and Dismukes 
2003; Pﬁ  zer 2005). Voriconazole 200 mg bid was approved 
for the treatment of EC in November 2004. In a randomized, 
double-dummy, double-blind, multicenter trial voriconazole 
200 mg bid was compared with ﬂ  uconazole 200 mg daily 
in esophageal candidiasis (Ally et al 2001). Overall success 
rates were comparable 98.2% for voriconazole compared 
with 95% for ﬂ  uconazole. The overall safety and tolerability 
of both agents was similar.
The echinocandins are a relatively new class of anti-
fungal, with a completely different mechanisms of action 
(Groll and Walsh 2003). All three are broad-spectrum and 
demonstrate excellent in vitro activity against most Candida 
species, including those species that are ﬂ  uconazole-resistant 
(Groll and Walsh 2003). All three echinocandins have been 
approved for the treatment of EC. Thus far, 5 different 
clinical trials evaluating echinocandins in EC have been 
completed. The clinical studies compare the echinocandins 
to either ﬂ  uconazole or amphotericin B (Groll and Walsh 
2003). Overall, all three echinocandins demonstrated Therapeutics and Clinical Risk Management 2007:3(4) 537
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non-inferiority to the comparator in each of the ﬁ  ve clinical 
trials. In addition, the overall safety proﬁ  le was excellent for 
the three echinocandins. The two major concerns with the 
echinocandins in the management of EC are that there are 
no oral formulations thus mandating the use of parenteral 
therapy for a minimum of 2–3 weeks, or a switch to an oral 
azole, and the relapse rates of EC using the echinocandins 
appears to be slightly higher than the comparators (ﬂ  ucon-
azole or amphotericin B). Nevertheless, clinical relapse is 
not uncommon, particularly in patients with persistence of 
underlying immunodeﬁ  ciency (eg, AIDS, chronic mucocu-
taneous candidiasis). Relapse appears to depend on duration 
of therapy and degree of immunosuppression, and may occur 
sooner following clotrimazole and ketoconazole therapy than 
after itraconazole or ﬂ  uconazole therapy (DeWit et al 1989; 
Vazquez and Sobel 1999).
The clinical impact of antifungal resistance in patient 
with AIDS has been demonstrated in patients who fail stan-
dard antifungal therapy for OPC (Vazquez and Sobel 1997). 
After the onset of ﬂ  uconazole-resistant thrush, patients had 
a median survival of 184 days. Moreover, after the onset of 
clinical resistance to amphotericin B, the patients had an 
astonishing 83-day median survival rate. Although mucosal 
candidiasis does not produce death directly, clinical failure 
is probably a co-morbidity factor in the rapid demise of these 
patients. Clinical failure is also a marker of severe immuno-
suppression and a nonfunctional immune system.
It is still not clear whether the total dose of antifungals, 
the duration of therapy, type of antifungal, or pattern of drug 
administration (continuous or episodic) are the most impor-
tant determinants in the development of antifungal-refrac-
tory fungal disease (Maenza et al 1996). More than likely 
it is multifactorial, involving a combination of advanced 
immunosuppression, high fungal burdens, and prolonged 
exposure to antifungals (McCarthy et al 1991).
In addition to microbial resistance, reasons for recurrence 
of OPC or refractory disease include patient non-compliance, 
the degree of immunosuppression, drug interactions, and 
altered drug bioavailability (Maenza et al 1996). These 
limitations underscore the need for new agents that may 
provide advantages such as safer delivery, fewer drug-drug 
interactions, and an improved antifungal spectrum.
Posanconazole (Noxaﬁ  l®, Schering-Plough) is a potent, 
oral extended-spectrum triazole antifungal recently approved 
by the FDA (Herbrecht 2004) (Figure 1). It is approved for the 
treatment of OPC, including OPC refractory to itraconazole 
and/or ﬂ  uconazole and for the prophylaxis of infections due 
to Candida and Aspergillus spp. in patients who are at high 
risk for such infections, such as those undergoing hemato-
poietic stem cell transplant (HSCT) with graft-versus host 
disease or with prolonged neutropenia due to a hematologic 
malignancy or its treatment (Schering Corp 2006).
Posaconazole, like other azole antifungals, inhibits 
lanosterol 14-alpha demethylase (CYP51), an enzyme that 
catalyzes the ﬁ  nal step in the synthesis of ergosterol, an 
important component of the fungal cell membrane (Munayyer 
et al 2004). Mutations near the heme cofactor of CYP51 
appear to reduce the binding afﬁ  nity of compact azoles 
such as ﬂ  uconazole and voriconazole and may lead to azole 
resistance in C. albicans (Li et al 2004). However, results of 
a study using 3-dimensional binding models suggest that the 
long side chain of posaconazole may result in tighter binding 
afﬁ  nity and appears to stabilize binding. It appears that muta-
tions in the heme site have far less impact on the susceptibility 
Figure 1 Structure of posaconazole.Therapeutics and Clinical Risk Management 2007:3(4) 538
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of the organisms to posaconazole, compared with ﬂ  uconazole 
or voriconazole. Thus a greater number of mutations may 
be required to generate resistance to posaconazole than to 
ﬂ  uconazole or voriconazole (Chau et al 2004; Li et al 2004; 
Xiao et al 2004). In addition, posaconazole is a substrate 
of the major facilitator pumps encoded by CDR1 and 
CDR2 in C. albicans, but is not a substrate of the major 
facilitator pumps encoded by MDR1 and FLU1 that efflux 
fluconazole (Heimark et al 2002). Posaconazole may be 
less susceptible than some azoles to the development of 
secondary azole resistance. In essence, although flucon-
azole and even voriconazole may demonstrate resistance 
to fluconazole, the majority of the time posaconazole will 
retain its in vitro susceptibility (Chau et al 2004; Li et al 
2004; Xiao et al 2004).
In vitro activity
Posaconazole has demonstrated in vitro activity against 
Aspergillus, Fusarium and the Zygomycetes. Its activity in 
vitro against Candida spp. is similar to that of voriconazole, 
and includes itraconazole- and ﬂ  uconazole-resistant strains 
of Candida, such as C. glabrata, and C. krusei (Sabatelli 
et al 2006). In vitro assays demonstrate posaconazole 
MIC90 values for C. albicans, C. parapsilosis, C. tropicalis, 
C. lusitaniae, and C. dubliniensis of 0.06–0.5 µg/mL, while 
MIC90 values for C. krusei and C. glabrata range from 0.5 




Posaconazole is orally absorbed, with the greatest exposure 
achieved when it is administered as an oral suspension (Courtney 
et al 2003a). Following administration of rising single or multiple 
doses (tablet formulation) to healthy subjects, posaconazole 
exhibits dose-proportional pharmacokinetics up to 800 mg/day 
(Courtney et al 2003b). No increase in area under the plasma 
concentration-time curve (AUC) values is observed when the 
posaconazole dose is increased from 800 to 1200 mg/day. Fol-
lowing administration of the tablet or suspension formulations, 
posaconazole has an extensive volume of distribution (343–1341 
L) and a long half-life (t1/2 approximately 25–35 h) (Courtney 
et al 2003a, b, c), with peak plasma concentrations attained at 
approximately 5–6 hours after dose. Steady state concentrations 
are attained at 7–10 days.
Posaconazole exposure is enhanced by co-administration 
with food. In a randomized, single-dose, open-label study 
conducted in 20 healthy male volunteers, administration of 
posaconazole with non-fat meal and a high-fat meal increased 
the AUC(0–72) 2.6- and 4-fold, respectively (p < 0.001 
vs administration under fasting conditions) (Courtney 
et al 2004). Similarly, administration of posaconazole with 
a nutritional supplement (Boost® Plus; MeadJohnson® 
Nutritionals, Evansville, Indiana, USA) increased maximum 
plasma concentrations (Cmax) and AUC(0  –72) 3.4- and 2.6-fold, 
respectively (Courtney et al 2003c).
When food intake is limited because of mucositis or 
other gastrointestinal dysfunction, dividing the daily dose 
enhances posaconazole’s bioavailability. In a study of healthy 
male volunteers (n = 18) given posaconazole 800 mg/day 
under fasted conditions, 200 mg qid and 400 mg bid dosing 
was associated with increases in Cmax and time to maximum 
Table 3 In vitro susceptibilities of Candida spp. to posaconazole, ﬂ  uconazole, and itraconazole
 Posaconazole  Fluconazole  Itraconazole
Organism  Range  50%  90% Range  50% 90%  Range  50%  90%
C. albicans  ≤0.004–16 0.003  0.06 0.12–  >64  0.25 0.5  <0.004–16 0.003 0.12
C. glabrata  0.3– >4  0.5  2.0  0.25– >64  16  >64  0.03– >4  1  8
C. parapsilosis  0.03–0.12 0.12  0.12  0.12–2.0 0.5 1  0.015–0.25  0.12 0.12
C. tropicalis  0.03– > 4  0.12  0.12  0.12– >64  0.5  2.0  0.015– >4  0.12  0.5
C. krusei  0.03–0.5 0.5  0.5  8–  >64 32  >64  0.12–2  0.5 0.5
C. dublinieusis  0.015–0.25 0.30  0.06 0.12–  >64 0.12 0.5  0.015–0.5  0.06  0.25
C. lusitaniae  0.015–0.12 0.12  0.12 0.12–8  1  2  0.03–0.5  0.12  0.5
Table 4 Pharmacokinetics of posaconazole
Variable Value
Volume of distribution (L)  1774
Protein binding (%)  >98
Elimination  Via feces (77%)
  Via urine (1%)
Half-life (hours)  35 (20–66)
Metabolism  Biotranformation via UDG pathway
Derived from data of Herbrecht (2004).
Abbreviations: UDG, uridine diphosphate – glucoronosyltransferaseTherapeutics and Clinical Risk Management 2007:3(4) 539
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plasma concentrations (tmax) compared with once-daily 
dosing (Ezzet et al 2006). Administration in split doses also 
improved estimated AUC, which doubled and tripled with 
twice-daily and qid dosing, respectively.
Metabolism/elimination
Posaconazole is primarily metabolized in the liver, where 
it undergoes glucuronidation and transformation into 
other biologically inactive metabolites (Krieter et al 2002). 
Approximately, 14% of an administered dose is excreted as 
multiple glucuronidated derivatives in the urine; an additional 
77% is eliminated as parent compound in the feces. Minor 
amounts are excreted as parent compound in the urine.
Unlike itraconazole and voriconazole, posaconazole is not 
primarily metabolized by fungal cytochrome P450 enzymes 
(CYP450) (Wexler et al 2004). Thus, co-administering 
drugs that interact with the CYP450 enzyme system may 
alter itraconazole and voriconazole plasma concentrations, 
but is unlikely to alter posaconazole plasma concentrations. 
An evaluation of the effects of posaconazole on the vari-
ous CYP450 enzymes demonstrated an inhibitory effect on 
CYP3A4 activity, but no inﬂ  uence on the activity of the other 
isoenzymes (CYP1A2, CYP2C8/9, CYP2D6 or CYP2E1) 
(Wexler et al 2004). In contrast to other azoles that are known 
to inhibit a variety of CYP450 drug-metabolizing isoenzymes 
(Albengres et al 1998; Vazquez 1999; Venkatakrishnan et al 
2000), posaconazole is unique in that its effects on CYP450 
enzyme activity are relatively limited. Therefore, posacon-
azole has the potential for fewer drug interactions compared 
with other azoles.
Special populations
Posaconazole pharmacokinetics are not signiﬁ  cantly inﬂ  u-
enced by age, gender, or ethnicity (Courtney et al 2000a, d, e). 
Therefore, no dose adjustments are necessary to accommo-
date for differences in these patient factors. Furthermore, 
renal or hepatic impairment has no signiﬁ  cant inﬂ  uence on 
the pharmacokinetics of posaconazole (Courtney et al 2000b; 
Courtney et al 2003f).
Clinical trials
A multicenter, randomized, evaluator-blinded study compared 
the efﬁ  cacy of posaconazole 100 mg daily to ﬂ  uconazole 100 
mg daily for the treatment of OPC in patients infected with 
HIV (Vazquez et al 2006). The primary end point was deﬁ  ned 
as clinical success on day 14. Three-hundred ﬁ  fty subjects 
were enrolled into the study, 178 received posaconazole 
and 172 received ﬂ  uconazole. Clinical success occurred in 
91.7% of patients treated with posaconazole and 92.5% of 
those treated with ﬂ  uconazole, with a mycological success of 
68% in both arms. On follow up day 42, mycological success 
remained greater in the posaconazole group (40.6% vs 26.4%; 
p = 0.038) and fewer patients in this group had experienced 
clinical relapses (31.5% vs 38.2%). Although it did not 
meet statistical superiority, it appears that posaconazole was 
somewhat more effective than ﬂ  uconazole in preventing a 
clinical relapse 6 weeks after the conclusion of antifungal 
therapy. In general, adverse events were uncommon and were 
similar in both groups.
In a separate clinical trial, oral posaconazole was 
evaluated in the management of OPC/EC that was clinically 
refractory to either ﬂ  uconazole or itraconazole (Skiest et al 
2006). In this study, oral posaconazole was used in subjects 
with conﬁ  rmed OPC or EC who failed to improve on con-
ventional courses of either ﬂ  uconazole at 100 mg daily or 
itraconazole 200 mg daily for a minimum of 10 days. Study 
subjects received either posaconazole 400 mg bid for 3 days, 
followed by 400 mg daily for 25 days or posaconazole 400 
mg bid for 28 days. The primary end point was either cure 
or improvement after 28 days of therapy. In the modiﬁ  ed 
intent-to-treat population (MITT), 75% (132/176) of treated 
subjects achieved a clinical response to posaconazole. Clini-
cal response was similar in both dosing regimens (75.3% 
vs 74.7%). In addition, in the 43 patients who also had 
endoscopically proven EC, the clinical response rate was 
documented to be 74.4%.
Although in this study, patients were on study drug for 
a prolonged period of time (28 days), the overall incidence 
of adverse events associated with the study drug was low. 
The most commonly observed adverse events included diar-
rhea (11%), neutropenia (7%), ﬂ  atulence (6%), and nausea 
(6%). Only 8 patients discontinued posaconazole because of 
treatment-related adverse events. The study concluded that 
posaconazole is a safe and effective treatment option for 
patients with HIV infection suffering from azole-refractory 
OPC/EC.
To further evaluate the safety and efficacy of long-
term posaconazole in patients with azole-refractory 
OPC/EC, a non-comparative open-label study was per-
formed (Vazquez et al 2007). Subjects who responded to 
the above mentioned trial, were eligible for a long term 
suppressive study. During the study period all patients 
received posaconazole 400 mg twice daily for up to 3 
months. If patients were stable and clinically cured at 
three months, they were continued on therapy for up to 12 Therapeutics and Clinical Risk Management 2007:3(4) 540
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months. After the 12-month treatment course, 85.6% of 
subjects continued to remain symptom free. Posaconazole 
was well tolerated, with minimal adverse events. Overall, 
this study established that posaconazole at 400 mg twice 
daily demonstrated long-term safety, tolerability, and 
efficacy, thus offering a safe and long-term suppressive 
treatment option for HIV-infected subjects suffering from 
azole-refractory mucosal candidiasis.
Safety
Posaconazole has been relatively well tolerated in all clinical 
trials thus far. The most common adverse effects have been 
nausea and headache. Rash, dry skin, dizziness, paresthesias, 
and ﬂ  ushing have been described.
The most common adverse events reported in posacon-
azole clinical studies are of gastrointestinal in origin 
(eg, nausea, vomiting, dyspepsia, taste disturbance, 
diarrhea, and abdominal pain), as would be expected with 
a triazole (Herbrecht 2004; Skiest et al 2006; Vazquez 
et al 2006). Elevated liver enzyme levels are rarely 
reported, and most are mild to moderate in severity and 
are similar to those observed in placebo-treated subjects 
(Courtney et al 2003b; Skiest et al 2006). In healthy 
volunteers who received single or multiple posaconazole 
doses up to 1200 mg/day, no QT interval prolongation 
or other clinically relevant changes in electrocardiogram 
results have been observed (Courtney et al 2003b). Long-
term administration of posaconazole does not appear to 
be associated with a different adverse event profile than 
short-term administration (Raad et al 2006; Skiest et al 
2006; van Burik et al 2006; Vazquez et al 2007). Discon-
tinuations because of adverse events were described in 
only two study reports. One report indicated that 22 of 98 
patients with febrile neutropenia or refractory invasive 
fungal infections discontinued posaconazole therapy 
prematurely because of adverse events; however, most 
of these events were not related to posaconazole therapy 
(Ullmann et al 2006). The other report described one 
premature discontinuation because of nausea, vomiting 
and diarrhea, which were attributed to infection with 
Cryptosporidium and acid-fast bacteria, not posaconazole 
therapy (Pitisuttithum et al 2003).
Based on this limited number of subjects with severe underly-
ing diseases, it appears that the adverse event proﬁ  le is similar to 
that of ﬂ  uconazole, with the most common events gastrointestinal 
in origin and with low incidence of hepatic or renal toxicity or 
rash. Additionally, visual adverse events such as those seen with 
voriconazole have not been reported (Pﬁ  zer 2003).
Drug interactions
Posaconazole is only an inhibitor of CYP3A4, thus it may 
potentate the effect and toxicity of drugs metabolized by 
this enzyme, including phenytoin, midazolam, rifabutin, 
cyclosporine, and tacrolimus; if given with posaconazole, 
cyclosporine doses should be reduced by one-quarter and 
tacrolimus doses by two-thirds, and serum levels of each 
should be monitored. Concurrent use of posaconazole with 
ergot alkaloids, pimozide, cisapride, halofantrine, astemizole, 
and quinidine is contraindicated (Wexler et al 2004).
Dosage
The recommended dose of posaconazole for OPC is a loading 
dose of 100 mg (2.5 mL) by mouth twice a day for the ﬁ  rst 
day, followed by 100 mg daily for 13 days. For refractory 
OPC, the recommended dosage is 400 mg (10 mL) twice 
daily based on the severity of illness. Most patients receive 
21–28 days of antifungal therapy. Posaconazole should be 
administered along with a full meal or with a liquid nutritional 
supplement. According to the manufacturer, if a full meal 
or supplement cannot be taken, alternative antifungal agents 
should be considered.
Conclusions
Numerous advances in antifungal therapy have been made 
in the last decade. The impressive results and minimal toxic-
ity of azole compounds continue to make them attractive in 
the management of fungal infections in patients with AIDS. 
However, difﬁ  culties in managing these infections should 
remind us that we cannot rely on antifungals alone. We must 
continue to ﬁ  nd ways to improve the body’s dysfunctional 
immune system. In addition, we must continue to develop 
more effective antifungal agents with different mechanisms 
of action and different modes of administration.
Clinical trials demonstrate that posaconazole is as ef-
fective as ﬂ  uconazole in producing a successful outcome in 
HIV-infected patients with OPC. In addition, posaconazole 
was more effective than ﬂ  uconazole in sustaining clinical 
success after completing antifungal therapy. Furthermore, in 
a separate long-term clinical trial, posaconazole also dem-
onstrated to be effective in HIV-infected patients suffering 
from azole-refractory OPC/EC. In the several clinical trials 
conducted thus far, posaconazole has been established as an 
extremely safe and very tolerable antifungal agent, similar 
to either ﬂ  uconazole or itraconazole.
Overall, posaconazole’s extended spectrum of activity, 
tolerability, long-term efﬁ  cacy, safety proﬁ  le and ease of use 
verify that it is an important addition to the antifungal arma-Therapeutics and Clinical Risk Management 2007:3(4) 541
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mentarium used to manage OPC and EC in any population. 
Posaconazole has also proven to be especially effective in 
the difﬁ  cult to treat HIV-infected population suffering from 
azole refractory MC.
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